ZENITH
KEEPING HOPES ALIVE

ZENITH DRUGS LIMITED
(Formerly - Zenith Drugs Private Limited)
CONTACT US:
www.zenithdrugs.com
info@zenithdrugs.com
+91 93291 45074 CIN: L24231MP2000PLC014465
Plant Add. - 72/5 & 72/1, 72/3, 74/1/1, 75/1/1 Muradpura (Orangpura), Dhar Road, Near Kalaria, INDORE, PIN-453001 (MP) INDIA

Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: August 26, 2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Sub: Outcome of Meeting of Board of Directors held on August 26, 2026.

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., Wednesday, August 26, 2026, considered and approved the following matters:

1. Re-designation of Mr. Ajay Singh Dassundi

The Board of Directors considered and approved the re-designation of Mr. Ajay Singh Dassundi from Executive Director to Non-Executive (Non-Independent) Director of the Company, with effect from August 27, 2026, subject to such approvals as may be required.

Consequent upon the aforesaid re-designation, Mr. Ajay Singh Dassundi shall continue as a Director of the Company in the capacity of Non-Executive (Non-Independent) Director.

The requisite disclosure as required under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as **Annexure-A**.

2. Allotment of Convertible Warrants

This is in continuation of our earlier intimations dated July 23, 2026, regarding the approval of the shareholders of the Company, we had received the In-principle approval from The National Stock Exchange of India Limited, for the issuance and allotment of convertible warrants by way of preferential issue on a private placement basis.

In this regard, kindly note that the Board of Directors, at its meeting held today, i.e., Wednesday, August 26, 2026, has, pursuant to the receipt of Rs. 1,74,98,421/- (Rupees One Crore Seventy Four Lakh Ninety Eight Thousand Four Hundred and Twenty one Only), being 25% of the aggregate consideration payable towards subscription of the warrants by all allottees, considered and approved the allotment of 16,09,050 (Sixteen Lakh Nine Thousand and Fifty) convertible warrants to persons belonging to the Promoter Category as detailed in "Annexure-C".

The details as required under Regulation 30 of the Listing Regulations, read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as "Annexure-B".

The Board meeting commenced at 12:30 P.M. and concluded at 12:52 P.M.

Thanking you
Yours faithfully

For Zenith Drugs Limited

SAKSHI BHAWSAR
Digitally signed by SAKSHI BHAWSAR
Date: 2026.08.26 13:04:01 +05'30'

SAKSHI BHAWSAR
Company Secretary and Compliance Officer

Annexure – A

S. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death, retirement or otherwise	Mr. Ajay Singh Dassundi (DIN: 07034128) has re-designated from Executive Director to Non-Executive (Non-Independent) Director of the Company..
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	The re-designation is effective from August 27, 2026. Mr. Ajay Singh Dassundi shall continue as a Director of the Company in the capacity of Non-Executive Director.
3.	Shareholding, if any, in the company	No. of shares held 3861990 (22.52%)
4.	Brief profile (in case of appointment)	Not Applicable.
5.	Disclosure of relationships between directors	Not Applicable.
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COM P/14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, dated 20th June, 2018	Not Applicable.

ANNEXURE B

The details as required to be disclosed under Regulation 30 read with SEBI Circular dated January 30, 2026:

Sr. No	Particulars	Details
1	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.	Warrants convertible into Equity Shares of Rs. 10/- each, i.e., 1 equity share for 1 warrant
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue on private placement basis
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Issue of Up to 16,09,050 (Sixteen Lakh Nine Thousand Fifty Only) Convertible Warrants into equity shares Issue of up to 16,09,050 (Sixteen Lakh Nine Thousand Fifty Only) Warrants at a price of Rs. 43.50/- (Rupees Forty-Three and Fifty paisa Only) per Warrant, each convertible into 1 (one) Equity Share of face value of Rs. 10/- (Rupees Ten Only) each fully paid up at a premium of Rs. 33.50/- (Rupees Thirty-Three and Fifty paisa Only) each per warrant ("Issue Price") in cash, for an aggregate consideration of up to Rs. 6,99,93,675/- (Rupees Six Crores Ninety Nine Lakhs Ninety Three Thousand Six Hundred and Seventy Five Only)
In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):		
A	Number of Proposed Allottee(s)	3 (Three)
B	Names of the Proposed Allotee(s)	***As per Annexure B as below***
C	Issue price for preferential allotment	Rs. 43.50/- per warrant including premium of Rs. 33.50/- (Rupees Thirty Three and Fifty paisa Only)
D	Post allotment of securities- outcome of the subscription, issue price allotted price (in case of convertibles), number of investors	The details of securities, prior to and after the proposed preferential allotment, are as under: "***Please refer Annexure B below***"
E	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	The warrant holders are, subject to the SEBI (ICDR) Regulations and other applicable rules, regulations and laws, entitled to exercise the warrants in one and more tranches within a period of 18 months from the date of allotment of the warrant by issuing a written notice to the company specifying the number of warrants proposed to be exercise. The Company shall accordingly issue and allot the corresponding number of equity shares of face value of Rs. 10/- each to the warrants holders; An amount equivalent to 25% of the warrant issue price to be received at the time of subscription and allotment of each warrants and the balance 75% shall be payable by the warrants holder(s) on exercise of warrant(s); In the event that, a warrant holder does not exercise the warrants within a period of 18 months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrants holders on such warrants shall stand forfeited by the Company
F	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable

Annexure C

Sr. No.	Name of the Proposed Allottee	No. of Convertible warrant into equity share (upto)	Category	Pre-preferential Issue Shareholding Percentage of the proposed allottees	% of Pre Issue Holding	*Post preferential Issue Shareholding of the proposed allottees	% of Post Issue Holding
1	AJAY SINGH DASSUNDI	5,36,350	Promoter	38,61,990	22.52%	43,98,340	23.44%
2	SANDEEP BHARDWAJ	5,36,350	Promoter	36,66,990	21.38%	42,03,340	22.40%
3	BHUPESH SONI	5,36,350	Promoter	34,60,980	20.18%	39,97,330	21.31%
	Total	**16,09,050**		**1,09,89,960**	**64.08%**	**1,25,99,010**	**67.16%**

* The above mentioned post preferential issue shareholding pattern of the Company is calculated on basis of assuming full subscription of convertible warrants into equity share to be allotted under the present issue.